Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants

Journal of Pediatrics

Volumn 142, Issue 2, 2003, Pages 155-162

  Ho, Vincent C ^a   Gupta, Aditya ^b   Kaufmann, Roland ^b   Todd, Gail ^b   Vanaclocha, Francisco ^b   Takaoka, Roberto ^b   Fölster Holst, Regina ^b   Potter, Paul ^b   Marshall, Katherine ^b   Thurston, Mark ^b   Bush, Christopher ^b   Cherill, Robert ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DRUG VEHICLE; NONSTEROID ANTIINFLAMMATORY AGENT; PIMECROLIMUS;

ARTICLE; ASTHMA; ATOPIC DERMATITIS; BACTERIAL SKIN DISEASE; BRONCHITIS; CAREGIVER; CHILDHOOD DISEASE; CLINICAL TRIAL; CONTACT DERMATITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE CONTROL; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; ECZEMA; ERYTHEMA; FEMALE; FEVER; GASTROENTERITIS; HUMAN; IMMUNOMODULATION; INFANT; INFANT DISEASE; INFLUENZA; IRRITANT DERMATITIS; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; RHINITIS; RHINOPHARYNGITIS; STATISTICAL SIGNIFICANCE; TONSILLITIS; TOOTH ERUPTION; UPPER RESPIRATORY TRACT INFECTION;

EID: 0037324145     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1067/mpd.2003.65     Document Type: Article

References (26)

1. Schultz LF. The epidemiology of atopic dermatitis. Monogr Allergy 1993;31:9-28.
2. Kay J, Gawkrodger DJ, Mortimer MJ, Jaron AG. The prevalence of childhood atoplc eczema in a general population. J Am Acad Dermatol 1994;30:35-9.
3. Wadonda N, Golding J, Kennedy CTC, Archer CB, Dunnill MGS. Prevalence of atopic eczema in children aged between 0 and 30 months in Avon district. Br J Dermatol 2000;143:33.
4. Williams HC, Wuthrich B. The natural history of atopic dermatitis. In: Williams HC, editor. Atopic dermatitis: the epidemiology, causes and prevention of atopic eczema. Cambridge: Cambridge University Press; 2000. p. 41-59.
5. Rudikoff D, Lebwohl M. Atopic dermatitis. Lancet 1998;351:1715-21.
6. Raimer SS. Managing pediatric atopic dermatitis. Clin Pediatr (Phila) 2000;39:1-14.
7. Gunther S. Incidence and degree of unwanted adverse effects of corticoids in children: results of dermatological studies in children with chronic diseases in the age group of 1-15 years. Z Hautkr 1976;51:569-79.
8. McLean C, Lobo R, Brazier D. Cataracts, glaucoma, and femoral avascular necrosis caused by topical corticosteroid ointment. Lancet 1995;345:330.
9. Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C. Cushing's syndrome after topical application of corticosteroid. Am J Dis Child 1982;136:274-5.
10. Hill CJ, Rosenberg A Jr. Adverse effects from topical steroids. Cutis 1978;21:624-8.
11. Bode HH. Dwarfism following long-term topical corticosteroid therapy. JAMA 1980;244:813-4.
12. Quielle C, Pommarede R, Saurat JH. Efficacy versus systemic effects of six topical steroids in the treatment of atopic dermatitis of childhood. Pediatr Dermatol 1984;1:246-53.
13. Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol 2000;142:931-6.
14. Meingassner JG, Grassberger M, Fahrngruber H, Moore HD, Schuurman H, Stütz A. A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology. Br J Dermatol 1997;137:568-76.
15. Hultsch T, Muller KD, Meingasser JG, Grassberger M, Schoff RE, Knop J. Ascomycin macrolactam derivative 502 ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner. Arch Dermatol Res 1998;290:501-7
16. Grassberger M, Baumruker T, Enz A, Hiestand P, Hultsch T, Kalthoff F, et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol 1999;141:264-73.
17. Zuberbier T, Chong S-U, Grunow K, Guhl S, Walker P, Grassberger M, et al. The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils. J Allergy Clin Immunol 2001;108:275-80.
18. Queille-Roussel C, Paul C, Duteil L, Lefebvre M-C, Rapatz G, Zagula M, et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br J Dermatol 2001;143:1-8.
19. Wahn U, Pariser D, Gottlieb AB, Kaufmann R, Eichenfield L, Langley R, et al. Low blood concentrations of SDZ ASM 981 in infants with extensive atopic dermatitis treated with cream 1%. J Eur Acad Dermatol Venereol. In press.
20. Eichenfield L, Lucky A, Boguniewicz M, Langley R, Cherill R, Marshall K, et al. Safety and efficacy of ASM 981 (pimecrolimus) cream 1% in the treatment of atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002;46:495-504.
21. Wahn U, Bos JD, Goodfield M, Caputo R, Papp K, Manjra A, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002;110:e2.
22. Seymour JL, Keswick BH, Hanifin JM, Jordan WP, Milligan MC. Clinical effects of diaper types on the skin of normal infants and infants with atopic dermatitis. J Am Acad Dermatol 1987;17:988-97.
23. US Food and Drug Administration. Guidance for industry. E6 good clinical practice: consolidated guidance. Federal Register 1997;10:25691-709.
24. Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. Exp Dermatol 2001;10:11-8.
25. Meingassner JG, Fahrngruber H, Bavandi A. SDZ ASM 981 oral shows activity against murine allergic contact dermatitis, different from FK 506 and cyclosporin A. J Eur Acad Dermatol Venereol. In press.
26. Reid P, Lewis-Jones MS. Sleep difficulties and their management in preschoolers with atopic eczema. Clin Exp Dermatol 1995;20:38-41.